메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 17, 2025 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies. Under the terms of the agreement, Harbour BioMed will collaborate with Bristol Myers Squibb to advance and accelerate multi-specific antibody discovery pro
- 김갑성 기자
- 2025-12-17 08:04
Jiaying Pharmaceutical: A New Pathway for the Industrialization of Century-Old Hakka Medicine

HONG KONG, Dec. 17, 2025 -- Recently, Meizhou in Guangdong, known as the "World Capital of the Hakka", welcomed a globally watched event, the Seventh World Hakka Entrepreneurs Convention. At this gathering that drew the attention of Hakka entrepreneurs worldwide, Guangdong Jiaying Pharmaceutical Co., Ltd. made a brilliant appearance with its star products, including Double-ingredient Throat Wind Relief Powder, Solid Essence Ginseng and Antler Pill, and Borneol Ointment, showcasing to the world the unique charm of Hakka medicine. Amid the wave of globalization, traditional Chi
- 김갑성 기자
- 2025-12-17 08:00
Leaders Dental Unveils Vision to Become "The Central Hub of the Digital Dentistry Ecosystem," Accelerates AI and IoT-Driven Production Automation

SEOUL, South Korea, Dec. 17, 2025 -- Leaders Dental Laboratory, a leading force in Korea's digital dental technology sector, has announced a new vision to position itself as "the central hub of the digital dentistry ecosystem." To realize this vision, the company is making significant investments in AI-CAD, 3D printing, and IoT-based production automation. With the Korean implant market approaching saturation, Leaders Dental aims to secure long-term competitiveness by investing aggressively in next-generation technologies and expanding its reach beyond the domestic market into the g
- 김갑성 기자
- 2025-12-17 06:00
All CONEC Signs MOU with MINIMAX, Taking First Step in Standardizing Digital Implant Production

SEOUL, South Korea, Dec. 17, 2025 -- All CONEC has signed a memorandum of understanding (MOU) with Australian digital dental company MINIMAX to establish a collaborative framework for digital implant production and lay the groundwork for overseas market entry. Digital implant production faces challenges due to differences in national product standards, production protocols, and communication methods. This partnership allows All CONEC to establish platform-based production standards at an early stage. The collaboration covers validating implant guide and prosthetic production pro
- 김갑성 기자
- 2025-12-17 06:00
The World's First AI Orchestrator Data Platform for Healthcare Launches

[ 메디채널 김갑성 기자 ] Orchestral – a Pioneering AI Orchestrator Data Platform Built for Healthcare AUCKLAND, New Zealand, Dec. 17, 2025 -- McCrae Tech has launched the world's first health AI orchestrator. The product, called Orchestral, is a health-native AI orchestrator data platform. It seamlessly connects diverse data sources with AI agents, workflows, and algorithms – enabling scalable, governed AI deployment across healthcare systems. "Most information technology in healthcare falls into two camps: either a big, dumb bucket of cloud data or isolated pockets of AI
- 김갑성 기자
- 2025-12-17 02:00
KPM Analytics Unveils the SmartChem® 800 Series, a Next-Generation Platform for High-Throughput Wet Chemistry

Industry's highest-capacity discrete analyzer delivers true walk-away automation for commercial laboratories WESTBOROUGH, Mass., Dec. 16, 2025 -- Commercial laboratories face mounting pressure to process more samples with fewer staff while maintaining fast turnaround times. When urgent samples arrive midday, labs face an impossible choice: disrupt current analyses to accommodate rush orders, or make clients wait. Meanwhile, technicians spend hours monitoring instruments and managing complex workflows across multiple analyzers—an unsustainable approach given persistent staffing
- 김갑성 기자
- 2025-12-16 22:00
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development

The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials The financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic therapeutics SHANGHAI, Dec. 16, 2025 -- Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on developi
- 김갑성 기자
- 2025-12-16 21:30
Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer

BEIJING, Dec. 16, 2025 -- METiS TechBio ("METiS") today announced that two of its oncology pipeline candidates, MTS-105 and MTS-107, have been published in leading international peer-reviewed journals, Nature Communications and the Journal for ImmunoTherapy of Cancer (JITC), representing two major breakthroughs in mRNA-based cancer therapeutics. Both studies leverage METiS's proprietary AI-powered NanoForge platform, which introduces a precision-guided rocket-and-payload delivery analogy. By combining liver- and spleen-targeted lipid nanoparticle (LNP) delivery system
- 김갑성 기자
- 2025-12-16 18:59
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases

SAN FRANCISCO, Dec. 16, 2025 -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key oversea clinical studies: the U.S. pivotal clinical study (NCT06764940) of Utidelone Injection(UTD1) combined with capecitabine for the treatment of HER2-negative breast cancer brain metastases (BCBM). The study adopts a two-stage design and plans to enroll approximately 120 subjects. The primary endpoint is the central nervous system objective response rate (CN
- 김갑성 기자
- 2025-12-16 12:55
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development

The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials The financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic therapeutics SHANGHAI, Dec. 16, 2025 -- Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on developi
- 김갑성 기자
- 2025-12-16 08:30

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 16시 00분